Department of Pharmacology, National organization for drug control and research (NODCAR), Giza, Egypt.
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St, Cairo 11562, Egypt.
Toxicol Appl Pharmacol. 2020 May 1;394:114954. doi: 10.1016/j.taap.2020.114954. Epub 2020 Mar 18.
Learning and memory deficits are obvious symptoms that develop over time in patients with poorly controlled diabetes. Hyperactivity of the renin-angiotensin system (RAS) is directly associated with β-cell dysfunction and diabetic complications, including cognitive impairment. Here, we investigated the protective and molecular effects of two RAS modifiers, aliskiren; renin inhibitor and captopril; angiotensin converting enzyme inhibitor, on cognitive deficits in the rat hippocampus. Injection of low dose streptozotocin for 4 days resulted in type 1 diabetes. Then, poorly controlled diabetes was mimicked with ineffective daily doses of insulin for 4 weeks. The hyperglycaemia and pancreatic atrophy caused memory disturbance that were identifiable in behavioural tests, hippocampal neurodegeneration, and the following significant changes in the hippocampus, increases in the inflammatory marker interleukin 1β, cholinesterase, the oxidative stress marker malondialdehyde and protein expression of phosphorylated extracellular-signal-regulated kinase and glycogen synthase kinase-3 beta versus decrease in the antioxidant reduced glutathione and protein expression of phosphorylated glycogen synthase kinase-3 beta. Blocking RAS with either drugs along with insulin amended all previously mentioned parameters. Aliskiren stabilized the blood glucose level and restored normal pancreatic integrity and hippocampal malondialdehyde level. Aliskiren showed superior protection against the hippocampal degeneration displayed in the earlier behavioural modification in the passive avoidance test, and the aliskiren group outperformed the control group in the novel object recognition test. We therefore conclude that aliskiren and captopril reversed the diabetic state and cognitive deficits in rats with poorly controlled STZ-induced diabetes through reducing oxidative stress and inflammation and modulating protein expression.
学习和记忆缺陷是未经良好控制的糖尿病患者随时间发展出现的明显症状。肾素-血管紧张素系统 (RAS) 的过度活跃与β细胞功能障碍和糖尿病并发症直接相关,包括认知障碍。在这里,我们研究了两种 RAS 调节剂——阿利克仑(肾素抑制剂)和卡托普利(血管紧张素转换酶抑制剂)——对大鼠海马认知缺陷的保护和分子作用。连续 4 天注射低剂量链脲佐菌素可导致 1 型糖尿病。然后,用无效的每日胰岛素剂量模拟未经良好控制的糖尿病 4 周。高血糖和胰腺萎缩导致记忆障碍,可通过行为测试、海马神经退行性变以及海马内以下显著变化来识别:炎症标志物白细胞介素 1β、胆碱酯酶、氧化应激标志物丙二醛和磷酸化细胞外信号调节激酶和糖原合酶激酶-3β的蛋白表达增加,而抗氧化剂还原型谷胱甘肽和磷酸化糖原合酶激酶-3β的蛋白表达减少。用药物阻断 RAS 结合胰岛素可以纠正所有上述参数。阿利克仑稳定血糖水平并恢复正常的胰腺完整性和海马丙二醛水平。阿利克仑在被动回避测试中对早期行为改变表现出更好的保护作用,在新物体识别测试中,阿利克仑组的表现优于对照组。因此,我们得出结论,阿利克仑和卡托普利通过降低氧化应激和炎症以及调节蛋白表达,逆转了 STZ 诱导的未经良好控制的糖尿病大鼠的糖尿病状态和认知缺陷。